Other Publication Details
Mandatory Fields
Editorial
Krawczyk, J,Keane, N,Swords, R,O'Dwyer, M,Freeman, CL,Giles, FJ
2013
October
Perifosine - a new option in treatment of acute myeloid leukemia?
Published
1
Optional Fields
acute myeloid leukemia chronic lymphocytic leukemia perifosine PI3K/AKT pathway targeted molecular therapy ACUTE MYELOGENOUS LEUKEMIA AKT INHIBITOR PERIFOSINE PHOSPHOINOSITIDE 3-KINASE PATHWAY CELL-CYCLE PROGRESSION NF-KAPPA-B PHOSPHATIDYLINOSITOL 3-KINASE PI3K/AKT PATHWAY KINASE-B IN-VITRO PROAPOPTOTIC ACTIVITY
Introduction: Perifosine is a novel targeted oral Akt inhibitor. In preclinical leukemia models, perifosine has an independent cytotoxic potential but also synergizes well with other rationally selected targeted agents. The evidence from clinical trials supporting the use of perifosine in the therapy of leukemias is limited. The optimal dose and schedule have yet to be defined. However, given its favorable toxicity profile and mechanism of action, the therapeutic potential of perifosine should be evaluated in well-designed clinical trials.Areas covered: The role of the phosphatidylinositol-3 kinase (PI3K)/Akt zpathway in normal cells, cancer and leukemias is discussed. The mechanism of action of perifosine and the basic information on the development and chemical properties are summarized. The evidence from in vivo and in vitro studies is presented. The efficacy and side effect profile are summarized.Expert opinion: The safety and tolerability profile of perifosine are satisfactory. The evidence from clinical trials in patients with leukemias is very limited. The preclinical data are encouraging. Perifosine has the potential to play a role in the treatment of leukemias in the future. Its role needs to be confirmed in clinical trials.
1315
1327
DOI 10.1517/13543784.2013.826648
Grant Details
Publication Themes